Mutant PLP1 impairs COPII vesicle formation via ER calcium depletion in Pelizaeus-Merzbacher disease

Area of Science:

• Neuroscience
• Cell Biology
• Genetics

Background:

• Pelizaeus-Merzbacher disease (PMD) is an X-linked hypomyelinating leukodystrophy caused by mutations in the PLP1 gene.
• Accumulation of mutant PLP1 causes endoplasmic reticulum (ER) stress, but blocking apoptosis in the unfolded protein response (UPR) did not rescue disease phenotypes in mouse models.

Purpose of the Study:

• To identify critical cellular mechanisms underlying oligodendrocyte dysfunction in PMD beyond ER stress.
• To investigate the role of ER calcium (Ca2+) homeostasis and ER-Golgi trafficking in PMD pathogenesis.

Main Methods:

• Utilized cellular and molecular biology techniques to analyze ER Ca2+ levels and ER-Golgi trafficking in PMD models.
• Investigated the interaction between mutant PLP1, COPII vesicle formation components (Sec31A), and calcium-binding proteins (ALG-2, AnxA11).
• Assessed the impact of pharmacological interventions targeting ER Ca2+ levels on cellular phenotypes.

Main Results:

• Identified ER Ca2+ depletion and disrupted ER-Golgi trafficking as key pathologies in PMD.
• Demonstrated that mutant PLP1 impairs COPII vesicle formation by destabilizing Sec31A at ER exit sites, linked to Ca2+ dysregulation and altered protein interactions.
• Showed that pharmacological restoration of ER Ca2+ levels rescued COPII formation, mitigating cellular defects.

Conclusions:

• PLP1 mutations disrupt intracellular protein trafficking via ER Ca2+ depletion, contributing to oligodendrocyte dysfunction in PMD.
• These findings reveal novel cellular mechanisms in PMD pathogenesis and suggest ER Ca2+ homeostasis as a potential therapeutic target for PMD and other myelin disorders.